Isomorphic Labs, a drug discovery-focused spin-out of Google AI R&D division DeepMind, has partnered with pharmaceutical giants Eli Lilly and Novartis to leverage AI in discovering new medications to treat diseases, with combined deals valued at around $3 billion.
Isomorphic draws on DeepMind’s AlphaFold 2 AI technology to predict the structure of proteins in the human body, aiming to identify new target pathways to deliver drugs for fighting disease, despite some imperfections in the model.
The latest version of AlphaFold can accurately predict the structures of biological molecules, ligands, nucleic acids, and post-translational modifications, and Isomorphic is applying this new model to therapeutic drug design to characterize different types of molecular structures important for treating disease.
HEALTH
WORLD AFFAIRS
TECHNOLOGY
CREATIVE
